Screening for pulmonary and brain vascular malformations is the North American standard of care for patients with hereditary hemorrhagic telangiectasia (HHT): A survey of HHT Centers of Excellence
Vascular Medicine. Authors: Alexandra Kilian, Marianne S. Clancy, Scott Olitsky, James R. Gossage and Marie E. Faughnan.
This article is available for public use and does not require purchase.